Timothy Lazarek
Nurse Practitioner · San Diego, CANPI 1891881215
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2022 at $12,473 and has fallen 73.1% since, to $3,359 in 2025. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 956 payments — averaging $38.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$8K
- Sanofi$5K
- Mallinckrodt Hospital Products Inc.$4K
- Boehringer Ingelheim$3K
- Amgen$3K
- AbbVie$2K
- plus $11K from 33 others
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$250
What the payments were for
- Consulting fees$6,92419%
- Speaking & faculty fees$6,31517%
- Travel & lodging$3,1449%
- Food & beverage$20,38655%
- Education$610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 124 | $7,646 |
| Sanofi | 16 | $5,482 |
| Mallinckrodt Hospital Products Inc. | 61 | $4,476 |
| Boehringer Ingelheim | 38 | $3,349 |
| Amgen(2 entities) | 155 | $2,680 |
| AbbVie | 101 | $2,025 |
| Johnson & Johnson | 95 | $1,830 |
| ANI Pharmaceuticals, Inc. | 62 | $1,508 |
| Novartis | 66 | $1,155 |
| Fresenius Kabi USA, LLC | 1 | $1,125 |
| AstraZeneca(2 entities) | 40 | $952 |
| Pfizer | 43 | $897 |
| Aurinia Pharma U.S., Inc. | 21 | $786 |
| GSK | 35 | $770 |
| Lilly USA, LLC | 23 | $622 |
| Radius Health, Inc. | 7 | $192 |
| E.r. Squibb & Sons, L.L.C. | 7 | $177 |
| Actelion Pharmaceuticals US, Inc. | 15 | $169 |
| Kyowa Kirin, Inc. | 5 | $111 |
| Genentech USA, Inc. | 5 | $95 |
| Pacira Therapeutics, Inc. | 5 | $86 |
| Vision Quest Industries Inc. | 2 | $69 |
| Echosens North America, Inc. | 2 | $66 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $65 |
| Janssen Scientific Affairs, LLC | 1 | $63 |
| Octapharma USA, Inc. | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Ultragenyx Pharmaceutical Inc. | 2 | $46 |
| CSL Behring | 3 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $41 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Merck | 1 | $30 |
| Hospira, Inc. | 1 | $26 |
| Biocryst US Sales Co., LLC | 1 | $24 |
| Sobi, Inc | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,829 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 27 | $188,171 |
| Taltz AutoinjectorIxekizumab | 22 | $151,327 |
| Xeljanz XrTofacitinib Citrate | 15 | $85,536 |
| Enbrel SureclickEtanercept | 11 | $82,272 |
| Orencia ClickjectAbatacept | 11 | $61,842 |
| BenlystaBelimumab | 12 | $58,410 |
| Actemra ActpenTocilizumab | 11 | $51,803 |
| RasuvoMethotrexate/Pf | 11 | $5,600 |
| Hydroxychloroquine Sulfate | 115 | $5,577 |
| MethotrexateMethotrexate Sodium | 106 | $3,004 |
| Leflunomide | 54 | $1,872 |
| Cevimeline Hcl | 15 | $1,777 |
| Leucovorin Calcium | 27 | $1,522 |
| Duloxetine Hcl | 27 | $788 |
| Pilocarpine Hcl | 22 | $711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $770 | $58,41012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in San Diego
- Angelina CollinsSan Diego$356K
- Madison ShreeveSan Diego$310K
- Arlene OrtegaSan Diego$135K
- Stacey RossSan Diego$43K
- Melanie McGillowaySan Diego$33K
- Jeremy FlowersSan Diego$26K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.